100 related articles for article (PubMed ID: 32712320)
1. Investigation of cancer drug resistance mechanisms by phosphoproteomics.
Boulos JC; Yousof Idres MR; Efferth T
Pharmacol Res; 2020 Oct; 160():105091. PubMed ID: 32712320
[TBL] [Abstract][Full Text] [Related]
2. High ELF4 expression in human cancers is associated with worse disease outcomes and increased resistance to anticancer drugs.
Kafita D; Daka V; Nkhoma P; Zulu M; Zulu E; Tembo R; Ngwira Z; Mwaba F; Sinkala M; Munsaka S
PLoS One; 2021; 16(4):e0248984. PubMed ID: 33836003
[TBL] [Abstract][Full Text] [Related]
3. Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance.
Marusyk A; Janiszewska M; Polyak K
Cancer Cell; 2020 Apr; 37(4):471-484. PubMed ID: 32289271
[TBL] [Abstract][Full Text] [Related]
4. A Semiautomated Proteomics and Phosphoproteomics Protocol for the Identification of Novel Therapeutic Targets and Predictive Biomarkers in In Vivo Xenograft Models of Pediatric Cancers.
Lim Kam Sian TCC; Sun C; Cain JE; Steele JR; Hanchapola I; Stoychev S; Schittenhelm RB; Faridi P
Methods Mol Biol; 2024; 2806():229-242. PubMed ID: 38676807
[TBL] [Abstract][Full Text] [Related]
5. Polyploidy in Cancer: Causal Mechanisms, Cancer-Specific Consequences, and Emerging Treatments.
Conway PJ; Dao J; Kovalskyy D; Mahadevan D; Dray E
Mol Cancer Ther; 2024 May; 23(5):638-647. PubMed ID: 38315992
[TBL] [Abstract][Full Text] [Related]
6. Integrated Omics of Metastatic Colorectal Cancer.
Li C; Sun YD; Yu GY; Cui JR; Lou Z; Zhang H; Huang Y; Bai CG; Deng LL; Liu P; Zheng K; Wang YH; Wang QQ; Li QR; Wu QQ; Liu Q; Shyr Y; Li YX; Chen LN; Wu JR; Zhang W; Zeng R
Cancer Cell; 2020 Nov; 38(5):734-747.e9. PubMed ID: 32888432
[TBL] [Abstract][Full Text] [Related]
7. EFHD1 promotes osteosarcoma proliferation and drug resistance by inhibiting the opening of the mitochondrial membrane permeability transition pore (mPTP) by binding to ANT3.
Shen X; Ma M; Mi R; Zhuang J; Song Y; Yang W; Li H; Lu Y; Yang B; Liu Y; Wu Y; Shen H
Cell Mol Life Sci; 2024 May; 81(1):236. PubMed ID: 38795203
[TBL] [Abstract][Full Text] [Related]
8. New insights into the interaction between m6A modification and lncRNA in cancer drug resistance.
Jin Y; Fan Z
Cell Prolif; 2024 Apr; 57(4):e13578. PubMed ID: 37961996
[TBL] [Abstract][Full Text] [Related]
9. In Silico, In Vitro, and In Vivo Investigations on Adapalene as Repurposed Third Generation Retinoid against Multiple Myeloma and Leukemia.
Boulos JC; Chatterjee M; Shan L; Efferth T
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627164
[TBL] [Abstract][Full Text] [Related]
10. A pan-cancer analysis of SLC1A5 in human cancers.
Ni J; Dai W; Liu C; Ling Y; Mou H
Heliyon; 2023 Jun; 9(6):e17598. PubMed ID: 37408893
[TBL] [Abstract][Full Text] [Related]
11. Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma.
Boulos JC; Omer EA; Rigano D; Formisano C; Chatterjee M; Leich E; Klauck SM; Shan LT; Efferth T
Acta Pharmacol Sin; 2023 Nov; 44(11):2265-2281. PubMed ID: 37344563
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of Thymidylate Synthase and Dihydrofolate Reductase in Cancer Cells and the Effect of CK2α Silencing.
Wińska P; Sobiepanek A; Pawlak K; Staniszewska M; Cieśla J
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769342
[TBL] [Abstract][Full Text] [Related]
13. Insights into the roles and driving forces of CCT3 in human tumors.
Ma J; Song P; Liu X; Ma C; Zheng M; Ren X; Wang R; Liu W; Lu Z; Li J
Front Pharmacol; 2022; 13():1005855. PubMed ID: 36313331
[TBL] [Abstract][Full Text] [Related]
14. Mass Spectrometric-Based Proteomics for Biomarker Discovery in Osteosarcoma: Current Status and Future Direction.
Sirikaew N; Pruksakorn D; Chaiyawat P; Chutipongtanate S
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077137
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.
Jin P; Jiang J; Zhou L; Huang Z; Nice EC; Huang C; Fu L
J Hematol Oncol; 2022 Jul; 15(1):97. PubMed ID: 35851420
[TBL] [Abstract][Full Text] [Related]
16. The active kinome: The modern view of how active protein kinase networks fit in biological research.
Alganem K; Hamoud AR; Creeden JF; Henkel ND; Imami AS; Joyce AW; Ryan V WG; Rethman JB; Shukla R; O'Donovan SM; Meller J; McCullumsmith R
Curr Opin Pharmacol; 2022 Feb; 62():117-129. PubMed ID: 34968947
[TBL] [Abstract][Full Text] [Related]
17. Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells.
Boulos JC; Saeed MEM; Chatterjee M; Bülbül Y; Crudo F; Marko D; Munder M; Klauck SM; Efferth T
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832908
[TBL] [Abstract][Full Text] [Related]
18. Identification of Novel Anthracycline Resistance Genes and Their Inhibitors.
Kadioglu O; Elbadawi M; Fleischer E; Efferth T
Pharmaceuticals (Basel); 2021 Oct; 14(10):. PubMed ID: 34681275
[TBL] [Abstract][Full Text] [Related]
19. Proteomics and phosphoproteomics reveal key regulators associated with cytostatic effect of amino acid transporter LAT1 inhibitor.
Okanishi H; Ohgaki R; Okuda S; Endou H; Kanai Y
Cancer Sci; 2021 Feb; 112(2):871-883. PubMed ID: 33264461
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
